Department of Radiology, Stobhill Hospital, Glasgow, UK.
Clin Radiol. 2011 Dec;66(12):1193-6. doi: 10.1016/j.crad.2011.08.004. Epub 2011 Oct 2.
To assess patient outcome in a consecutive series of patients with myeloma and spinal metastases who underwent percutaneous vertebroplasty.
Data were gathered prospectively on all patients undergoing percutaneous vertebroplasty between June 2001 and June 2010. Outcome measures included visual analogue pain scores (VAS) and Roland-Morris Questionnaire (RMQ) in patients treated since 2005 as well as complications and long-term outcome in all patients.
One hundred and twenty-eight patients underwent percutaneous vertebroplasty for myeloma (n=41) or spinal metastases (n=87) over a 9 year period. VAS scores fell from 7.75 ± 1.88 pre-vertebroplasty to 4.77 ± 2.69 post-vertebroplasty (p=0.001). RDQ scores improved from 18.55 ± 4.79 to 13.5 ± 6.96 (p=0.001). Complications were recorded in three patients: cement extension to vena cava (n=1), local haematoma (n=1), and loss of sensation over T1 dermatome (n=1). The Kaplan-Meier estimate of 5 year survival post-vertebroplasty was 40% for patients with myeloma and 25% for those with metastases.
This large prospective study demonstrates percutaneous vertebroplasty reduces pain and improves disability in patients from intractable pain from myeloma or spinal metastases and now forms an important part of the multimodality treatment for these patients.
评估连续系列骨髓瘤伴脊柱转移患者行经皮椎体成形术的治疗效果。
前瞻性收集 2001 年 6 月至 2010 年 6 月期间所有行经皮椎体成形术患者的数据。疗效评估包括 2005 年后治疗的患者的视觉模拟疼痛评分（VAS）和 Roland-Morris 问卷（RMQ）以及所有患者的并发症和长期结果。
9 年间，128 例骨髓瘤（n=41）或脊柱转移患者（n=87）接受了经皮椎体成形术。VAS 评分从术前的 7.75±1.88 降至术后的 4.77±2.69（p=0.001）。RMQ 评分从 18.55±4.79 改善至 13.5±6.96（p=0.001）。3 例患者出现并发症：1 例骨水泥延伸至腔静脉，1 例局部血肿，1 例 T1 皮节感觉丧失。骨髓瘤患者经皮椎体成形术后 5 年生存率的 Kaplan-Meier 估计值为 40%，转移瘤患者为 25%。
这项大型前瞻性研究表明，经皮椎体成形术可减轻骨髓瘤或脊柱转移患者顽固性疼痛，并改善其残疾状况，现已成为这些患者多模式治疗的重要组成部分。
